<DOC>
	<DOCNO>NCT02766608</DOCNO>
	<brief_summary>This Phase III randomize , double-blind , parallel group , multi-center , 24-week lung function study BFF MDI ( 320/9.6 μg 160/9.6 μg ) compare FF MDI 9.6 μg , BD MDI 320 μg , open-label Symbicort® TBH ( 200/6 μg ) administer BID .</brief_summary>
	<brief_title>Study Assess Efficacy Safety PT009 Compared PT005 , PT008 , Symbicort® Turbuhaler® Lung Function Over 24-Weeks Subjects With Moderate Very Severe COPD</brief_title>
	<detailed_description>This Phase III randomize , double-blind , parallel group , multi-center , 24-week lung function study BFF MDI ( 320/9.6 μg 160/9.6 μg ) compare FF MDI 9.6 μg , BD MDI 320 μg , open-label Symbicort® TBH ( 200/6 μg ) administer BID . Subjects undergo 1- 4-week Screening Period . Subjects successfully complete Screening Period one follow five treatment group : BFF MDI 320/9.6 μg BID ( N=660 ) , BFF MDI 160/9.6 μg BID , FF MDI 9.6 μg BID , BD MDI 320 μg BID , Symbicort® , TBH 400/12 μg BID . Following randomization , subject enter Treatment Period undergo additional treatment visit 24 week .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Give signed write informed consent participate 2 . Are least 40 year age old 80 year 3 . COPD patient symptomatic 4 . Must receive one inhaled bronchodilator maintenance therapy 1 . Current diagnosis asthma , 2 . COPD due α1Antitrypsin Deficiency 3 . Known active tuberculosis , lung cancer , cystic fibrosis , significant bronchiectasis , Pulmonary resection Lung Volume Reduction Surgery past 6 month 4 . Longtermoxygen therapy ( ≥ 12 hour day ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
</DOC>